Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8292281 | 0.93 | SMN1; SMN2 (0.50) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL6160410 | 0.91 | MEN1 (0.50) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL6951672 | 0.91 | ALDH1A1 (0.48) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL6161501 | 0.89 | MEN1 (0.48) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL6161821 | 0.89 | PPIA (0.49) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL8301170 | 0.88 | CA1 (0.48) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL6162538 | 0.88 | MEN1 (0.47) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL8300521 | 0.88 | SMN1; SMN2 (0.45) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL8293109 | 0.87 | MEN1 (0.49) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL7976041 | 0.87 | MEN1 (0.46) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368461-B2 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| EP-1444220-B1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2005-09-15 | — | — | US | disclosed |
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| EP-1444220-A1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| EP-0680962-B1 | Heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003037889-A1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| EP-0734383-B1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | disclosed |
| US-6355695-B1 | ANTIHISTAMINES; ASTHMA THERAPY | ZENECA LIMITED (SE) | 2002-03-12 | — | — | US | disclosed |
| US-6235757-B1 | ANTIHISTAMINES | ZENECA LIMITED (GB) | 2001-05-22 | — | — | US | disclosed |
| US-5677317-A | Lactam compounds which are useful in the treatment of asthma | ZENECA LIMITED (GB) | 1997-10-14 | — | — | US | disclosed |
| US-5635509-A | ASTHMA; BRONCHODILATOR AGENTS; VASODILATION MICROVASCULAR PERMEABILITY; MAST CELLS | ZENECA LIMITED (GB) | 1997-06-03 | — | — | US | disclosed |
| US-5589489-A | Cyclic amide derivatives for treating asthma | ZENECA LIMITED (GB) | 1996-12-31 | — | — | US | disclosed |
| EP-0739891-A2 | Substituted heterocycles | ZENECA LIMITED (GB) | 1996-10-30 | — | — | EP | disclosed |
| EP-0734383-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1996-10-02 | — | — | EP | disclosed |
| EP-0726893-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| US-5534525-A | Lactam derivatives | ZENECA LIMITED (GB) | 1996-07-09 | — | — | US | disclosed |
| EP-0680962-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
| WO-1995016682-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-22 | — | — | WO | disclosed |
| WO-1995012577-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | TACR1, TACR2, BDKRB1 | MEN1 3131/4885KMT2A 2453/4885NPSR1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.